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Abstract: A 72 year old man with a history of TIAs and stroke with unexplained moderately raised ESR presented a year 
later with rapid deterioration of vision in his left eye because of central retinal vein occlusion. Primary antiphospholipid 
syndrome is found in patients with history of arterial or venous thromboembolism, thrombocytopenia and recurrent fetal loss 
without features of SLE. 
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Case report 
A seventy two year old man was referred by his GP with 
a history of tiredness, lethargy, stiff knees and hips and an 
ESR of 56 mm/hr. He gave a history of waking up with 
lethargy and memory loss. He was on treatment for 
hypercholesterolemia and he smokes 10 cigarettes a day.  
He had no history of headache or any other symptoms 
suggestive of temporal areteritis. On examination at that 
time he was found to be slightly overweight and had 
xanthelasma around his eyes. Pulse was 60/minute and 
regular and BP was 160/80. No carotid bruits was found 
and no tenderness over the temporal artery. The rest of 
the physical examination was normal. His ESR was 52 
mm/hr. Full blood counts, LFT, TFT, Vitamin B12, Red Cell 
Folate, VDRL, Autoimmune screening, Myloma screen, and 
chest x-ray were all within normal limits. CT Scan of his 
brain showed small vessel ischaemia with a small lacunar 
infarction. In view of the systemic risk factors and the CT 
Scan finding he was diagnosed with cerebrovascular 
disease. He was started on Aspirin 75mg , Perindopril 2mg 
and Benzofibrate 200 mg TDS as he was intolerant to 
Statins. 
 
Nine months later he presented to the eye clinic with 
rapid deterioration of vision in his left eye. His best 
corrected visual acuities were 6/9 and counting Fingers in 
the right and left eye respectively. He was found to have a 
left ischaemic central retinal vein occlusion with macular 
oedema (Figure 1). 
 
He was referred from the eye clinic again to the 
physician for reassessment. Thrombophilia screen was 
requested to exclude the possibility of a coagulation 
disorder. The result showed a very high Anticardiolipin 
IgM [80.3 MPL u/mL] normal value should be less than 9 
MPL u/mL.   The test was repeated twice and still showed 
a high level. Further investigations requested to exclude 
secondary antiphospholipid syndrome were normal 
including ultrasound scan of the abdomen, tumour 
markers and colonoscopy. His entire autoimmune screen 
remained negative apart from his anticardiolipin antibody. 
  
The risk of further thromboembolic complication was 
considered to be high. He was therefore started on long-
term Warfarin treatment. 
He has been under follow up for more than twelve 
months with no further events. His left eye showed signs 
of neovascular glaucoma and had full pan retinal Laser 
photocoagulation. His left eye remained stable during 
further follow up. 
Fig 1: Normal fundus 




We present a case of primary antiphospholipid 
syndrome in this patient where the diagnosis was not 
suspected initially because of his age and also the 
presence of multiple risk factors for cerebrovascular 
disease which has led to delay in investigating other 
causes of vascular thrombosis until he developed central 
retinal vein thrombosis.  The other presenting symptom 
was the recent memory loss which was initially hard to 
explain. However, cognitive dysfunction in 
antiphospholipid syndrome (APS) has been partially 
described, despite the increased interest in this area in 
recent years. A number of studies of patients with SLE and 
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healthy individuals have shown an association between 
positive aPL antibody findings and cognitive dysfunction 
[1-3] 
 
Tektonido et al [3] studied Sixty patients (39 with 
primary APS and 21 with systemic lupus erythematosus–
related APS) and 60 healthy individuals matched for age, 
sex, and education.  He found Twenty five (42%) of the 
60 patients with APS had cognitive deficits compared with 
11 (18%) healthy control subjects.  He concluded that 
Cognitive deficits may often be found among patients with 
APS, independent of any history of central nervous system 
involvement. Livedo reticularis and the presence of white 
matter lesions on brain magnetic resonance imaging are 
associated with an increased risk for cognitive dysfunction 
in APS. 
 
Antiphospholipid syndrome is a multisystem disorder 
with a wide range of neurological manifestations, and 
occurs more commonly in young to middle aged people 
[4]. Retinal vascular occlusive disease occurs infrequently 
and considering our patient’s age this makes the case 
unusual. Other features such as recurrent miscarriages, 
thrombocytopenia, and livedo reticularis, may complicate 
10 to 15 per cent of patients with systemic lupus 
erythematosus. When these features, together with the 
presence of antiphospholipid antibodies (usually 
cardiolipin, or the lupus anticoagulant) occur in the 
presence of other more classical lupus features, the 
condition is known as secondary antiphospholipid 
syndrome, but they can occur on their own, in which case 
the patient is said to have primary antiphospholipid 
syndrome. Pathological effects of antiphospholipid 
antibodies are not due to deposition and complement 
activation but due to activation of thrombus formation. 
This leads to arterial and venous thromboses that may be 
particularly harmful in the cerebral and renal circulation. 
The mechanism by which thrombosis is altered is not fully 
understood; antiphospholipid antibodies found in systemic 
lupus erythematosus and the primary antiphospholipid 
antibody syndrome recognize a complex of negatively 
charged phospholipids with the plasma protein 2-
glycoprotein 1. Antiphospholipid antibodies can be found 
in infectious diseases such as syphilis. 
 
The frequency of ocular vasculo-occlusive disorders in 
patients with this syndrome ranges from 0.5 to 8%, with 
the majority affecting the retinal vasculature. Both arterial 
and venous systems may be involved [5-7]. Retinal vein 
thrombosis, deep vein thrombosis, pulmonary embolism, 
sagittal vein thrombosis, cerebral artery occlusion and 
myocardial infarction as well as other venous or arterial 
thrombosis at various sites have been described in 
patients with Antiphospholipid syndrome [8-9] and 
therefore it is important to make the diagnosis at the 
earliest opportunity. 
 
The therapeutic approach to Antiphospholipid syndrome 
is still controversial. Immunosuppressant or high doses of 
corticosteroids to suppress the antiphospholipid antibodies 
have not proved to be sufficient. The management of 
acute thrombotic complications of Antiphospholipid 
syndrome is similar to the management in other clinical 
settings. However, patients with this syndrome are more 
prone to recurrent thrombotic events [10] therefore long 
term warfarin treatment is recommended.  
 
Key points 
• Presence of multiple risk factors for stroke should not 
discourage doctors from looking for other causes of 
thrombosis 
• Long term Warfarin treatment should be considered to 
reduce the recurrence of thrombotic events.  
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